Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

Phase 3

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Venetoclax
Drug: Cytarabine
Drug: Magrolimab
Drug: Azacitidine
Drug: Daunorubicin
Drug: Idarubicin
Drug: Steroidal Eye Drops

Registration Number: NCT04778397

Lead Sponsor: Gilead Sciences

Brief Summary: The goal of this clinical study is to compare the effectiveness of the study drugs, magrolimab in combination with azacitidine, versus venetoclax in combination with azacitidine in participants with previously untreated TP53 mutant acute myeloid leukemia (AML).

Detailed Description: Not available

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 258

Inclusion Criteria

Individuals with confirmation of acute myeloid leukemia (AML) by World Health Organization criteria, previously untreated for AML, and who have presence of at least 1 TP53 gene mutation that is not benign or likely benign based on evaluation by either central laboratory or an approved local laboratory (after central review of the bone marrow TP53 mitigation next-generation sequencing test results) (individuals with biallelic 17p deletions, loss of both 17p alleles, are eligible based on locally evaluated cytogenetics/karyotype/fluorescence in situ hybridization (FISH) report).
Individuals with white blood cell (WBC) count ≤ 20×10^3/microliter (μL) prior to randomization. If the individual's WBC is > 20×10^3/μL prior to randomization, the individual can be enrolled, assuming all other eligibility criteria are met. However, the WBC should be ≤ 20×10^3/μL prior to the first dose of study treatment and prior to each magrolimab dose the first 4 weeks (if the individual is randomized to the experimental arm) Note: Individuals can be treated with hydroxyurea and/or leukapheresis throughout the study or prior to randomization to reduce the WBC to ≤ 20×10^3/μL to enable eligibility for study drug dosing.
The hemoglobin must be ≥ 9 grams per deciliter (g/dL) prior to initial dose of study treatment.

Notes: Transfusions are allowed to meet hemoglobin eligibility.

Individual has provided informed consent.
Individual is willing and able to comply with clinic visits and procedure outlined in the study protocol.
Individuals must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, except for individuals less than 75 years of age and appropriate for non-intensive treatment. For these individuals, the ECOG performance status score may be 0 to 3.
Individuals must have adequate renal function as demonstrated by a creatinine clearance ≥ 30 milliliters per minute calculated by the Cockcroft Gault formula.
Adequate cardiac function as demonstrated by:
- Lack of symptomatic congestive heart failure and clinically significant cardiac arrhythmias and ischemic heart disease.
- Left ventricular ejection fraction (LVEF) > 50% for individuals appropriate for intensive therapy.
Adequate liver function as demonstrated by:
- Aspartate aminotransferase ≤ 3.0 × upper limit of normal (ULN).
- Alanine aminotransferase ≤ 3.0 × ULN.
- Total bilirubin ≤ 1.5 × ULN, or primary unconjugated bilirubin ≤ 3.0 × ULN if individual has a documented history of Gilbert's syndrome or genetic equivalent.
Pretreatment blood cross-match completed.
Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.
Individuals must be willing to consent to mandatory pretreatment and on-treatment bone marrow biopsies (aspirate and trephines).

Key

Exclusion Criteria

Positive serum pregnancy test.
Breastfeeding female.
Known hypersensitivity to any of the study drugs, the metabolites, or formulation excipient.
Prior treatment with any of the following:
- Cluster of differentiation 47 (CD47) or signal regulatory protein alpha (SIRPα)-targeting agents
- Antileukemic therapy for the treatment of AML (excluding hydroxyurea), hypomethylating agent (HMA), low dose cytarabine and/or venetoclax.

Note: Individuals with prior myelodysplastic syndrome (MDS) who have not received prior HMAs or chemotherapeutic agents for MDS are allowed on study. Other prior MDS therapies including, but not limited to, lenalidomide, erythroid stimulating agents, or similar red blood cell (RBC)-direct therapies, were allowed. Localized non-central nervous system (CNS) radiotherapy, erythroid and/or myeloid growth factors, hormonal therapy with luteinizing hormone-releasing hormone agonists for prostate cancer, hormonal therapy or maintenance for breast cancer, and treatment with bisphosphonates and receptor activator of nuclear factor kappa-B ligand inhibitors are also not criteria for exclusion.

Individuals who are appropriate for intensive treatment but who have been previously treated with maximum cumulative doses of idarubicin and/or other anthracyclines and anthracenediones will be excluded.
Individuals receiving any live vaccine within 4 weeks prior to initiation of study treatments.
For individuals appropriate for intensive therapy, individuals treated with trastuzumab within 7 months prior to initiation of study treatments.
Current participation in another interventional clinical study.
Known inherited or acquired bleeding disorders.
Individuals appropriate for non-intensive therapy, who have received treatment with strong and/or moderate cytochrome P450 enzyme 3A (CYP3A) inducers within 7 days prior to the initiation of study treatments.
Individuals appropriate for non-intensive therapy who have consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or starfruit within 3 days prior to the initiation of study treatment.
Individuals appropriate for non-intensive therapy who have malabsorption syndrome or other conditions that preclude enteral route of administration.
Clinical suspicion of active CNS involvement with AML.
Individuals who have acute promyelocytic leukemia.
Significant disease or medical conditions, as assessed by the investigator and sponsor, that would substantially increase the risk-benefit ratio of participating in the study. This includes, but is not limited to, acute myocardial infarction within the last 6 months, unstable angina, uncontrolled diabetes mellitus, significant active infections, and congestive heart failure New York Heart Association Class III-IV.
Second malignancy, except MDS, treated basal cell or localized squamous skin carcinomas, localized prostate cancer, or other malignancies for which individuals are not on active anti-cancer therapies and have had no evidence of active malignancy for at least ≥ 1 year Note: Individuals on maintenance therapy alone who have no evidence of active malignancy for at least ≥ 1 year are eligible.
Known active or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection or human immunodeficiency virus (HIV) infection in medical history.
Active HBV, and/or active HCV, and/or HIV following testing at screening:
- Individuals who test positive for hepatitis B surface antigen (HBsAg). Individuals who test positive for hepatitis B core antibody (anti-HBc) will require HBV deoxyribose nucleic acid (DNA) by quantitative polymerase chain reaction (PCR) for confirmation of active disease.
- Individuals who test positive for HCV antibody. These individuals will require HCV ribose nucleic acid (RNA) quantitative PCR for confirmation of active disease.
- Individuals who test positive for HIV antibody.
- Individuals not currently receiving antiviral therapy and who have an undetectable viral load in the prior 3 months may be eligible for the study.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control Arm: 7+3 Chemotherapy	Steroidal Eye Drops	Participants who are appropriate for intensive therapy will receive 7+3 chemotherapy: 7 day treatment with cytarabine and 3 day treatment with daunorubicin or idarubicin during induction and high-dose cytarabine and steroidal eye drops during consolidation.
Control Arm: Venetoclax + Azacitidine	Venetoclax	Participants who are appropriate for non-intensive therapy will receive an escalating dose of venetoclax and a fixed dose of azacitidine.
Magrolimab + Azacitidine	Azacitidine	Participants will receive an escalating dose of magrolimab and a fixed dose of azacitidine.
Control Arm: 7+3 Chemotherapy	Cytarabine	Participants who are appropriate for intensive therapy will receive 7+3 chemotherapy: 7 day treatment with cytarabine and 3 day treatment with daunorubicin or idarubicin during induction and high-dose cytarabine and steroidal eye drops during consolidation.
Control Arm: Venetoclax + Azacitidine	Azacitidine	Participants who are appropriate for non-intensive therapy will receive an escalating dose of venetoclax and a fixed dose of azacitidine.
Control Arm: 7+3 Chemotherapy	Daunorubicin	Participants who are appropriate for intensive therapy will receive 7+3 chemotherapy: 7 day treatment with cytarabine and 3 day treatment with daunorubicin or idarubicin during induction and high-dose cytarabine and steroidal eye drops during consolidation.
Control Arm: 7+3 Chemotherapy	Idarubicin	Participants who are appropriate for intensive therapy will receive 7+3 chemotherapy: 7 day treatment with cytarabine and 3 day treatment with daunorubicin or idarubicin during induction and high-dose cytarabine and steroidal eye drops during consolidation.
Magrolimab + Azacitidine	Magrolimab	Participants will receive an escalating dose of magrolimab and a fixed dose of azacitidine.

Primary Outcome Measures

Name	Time	Method
Overall Survival (OS) in Participants Appropriate for Non-intensive Therapy	Up to 2.1 years	OS was measured from the date of randomization to the date of death from any cause. Deaths which were not observed during the study were censored at their last known alive date. Kaplan-Meier (KM) estimates were used in outcome measure analysis.

Secondary Outcome Measures

Name	Time	Method
Overall Survival in All Participants	Up to 2.1 years	OS was measured from the date of randomization to the date of death from any cause. Deaths which were not observed during the study were censored at their last known alive date. KM estimates were used in outcome measure analysis.
Event-Free Survival (EFS) in All Participants	Up to 2.1 years	EFS: time from randomization to earliest relapse from CR (CR without minimal residual disease (CRMRD-) and CR with MRD positive/MRD unknown (CRMRD+/unk)), treatment failure (failure to achieve CR in 6 months of magrolimab/venetoclax+azacitidine; 2 months after chemotherapy), or death within the response window. CRMRD- and CRMRD+/unk: neutrophils \>1.0 ×10\^9/L, platelets \>100 ×10\^9/L, \<5% bone marrow blasts, no circulating blasts or extramedullary disease (confirmed by flow cytometry \<0.1% sensitivity for CRMRD-). Post-SCT assessments or new AML therapies were included. Date of randomization was assigned as event date for participants with treatment failure. Participants without events were censored at their last assessment. KM estimates were used for analysis.
Rate of Complete Remission (CR) in All Participants	Up to 2.1 years	The rate of CR was the percentage of participants who achieved a CR, including CR without minimal residual disease (CR MRD-) and CR with positive or unknown minimal residual disease (CR MRD+/unk) within 6 months of treatment with magrolimab + azacitidine or venetoclax + azacitidine, or within 2 months of treatment with 7 + 3 chemotherapy, as defined by investigators based on European Leukemia Net (ELN) 2017 AML (ELN 2017 AML) with modifications, while on study prior to initiation of any new anti-AML therapy or stem cell transplant (SCT) within the response assessment window of 2.1 years. CR MRD- and CR MRD+/unk are defined in Outcome Measure#3 (EFS). Percentages were rounded-off. Clopper-Pearson method were used in outcome measure analysis.
Rate of CR Without Minimal Residual Disease (CR MRD-) in All Participants	Up to 2.1 years	Rate of CR MRD- was the percentage of participants who achieve a CR MRD- within 6 months treatment with magrolimab + azacitidine or venetoclax + azacitidine, or within 2 months of treatment with 7 + 3 chemotherapy, as defined by investigators based on ELN 2017 AML with modifications, while on study prior to initiation of any new anti-AML therapy or SCT within the response assessment window of 2.1 years. CR MRD- is defined in Outcome Measure #3 (EFS). Percentages were rounded-off. Clopper-Pearson method were used in outcome measure analysis.
Rate of CR and CR With Partial Hematologic Recovery (CR+CRh) in All Participants	Up to 2.1 years	The CR+CRh rate was the percentage of participants who achieved a CR (including CR MRD- and CR MRD+/unk) or CRh as defined by CR with partial platelet and absolute neutrophil count (ANC) recovery within 6 months of treatment with magrolimab + azacitidine or venetoclax + azacitidine, or within 2 months of treatment with 7 + 3 chemotherapy while on study prior to initiation of any new anti-AML therapy or SCT up to the response assessment window of 2.1 years. CRh is defined as neutrophils \> 0.5 x 10\^9/L; platelets \> 50 x 10\^9/L; bone marrow blasts \< 5%; Absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease. CR MRD- and CR MRD+/unk are defined in Outcome Measure#3 (EFS). Percentages were rounded-off. Clopper-Pearson method were used in outcome measure analysis.
Duration of CR (DCR)	Up to 2.1 years	DCR was measured from the time the assessment criteria were first met for CR (including CR MRD- and CR MRD+/unk) within 6 months of treatment with magrolimab + azacitidine or venetoclax + azacitidine, or within 2 months of treatment with 7 + 3 chemotherapy, until the first date of AML relapse or death (including assessments post SCT). Participants who were not observed to have relapsed disease or death while on study were censored at the date of their last response assessment with no evidence of relapse. Participants who started taking new anti-AML therapies (excluding post-SCT maintenance therapy) before relapse, the DCR were censored at the last response assessment before the initiation of the new anti-AML therapies. CR MRD- and CR MRD+/unk are defined in Outcome Measure#3 (EFS). KM estimates were used in outcome measure analysis.
Duration of CR+CRh	Up to 2.1 years	Duration of CR+CRh was measured from the time the assessment criteria were first met for CR (including CR MRD- and CR MRD+/unk) or CRh within 6 months of treatment with magrolimab + azacitidine or venetoclax + azacitidine, or within 2 months of treatment with 7 + 3 chemotherapy, until the first date of AML relapse or death (including assessments post SCT). Participants who were not observed to have relapsed disease or death while on study were censored at the date of their last response assessment with no evidence of relapse. Participants who started taking new anti-AML therapies (excluding post-SCT maintenance therapy) before relapse, the duration of CR + CRh were censored at the last response assessment before the initiation of the new anti-AML therapies. CR MRD- and CR MRD+/un are defined in Outcome Measure #3. CRh is defined in Outcome Measure #6. KM estimates were used for outcome measure analysis.
Percentage of Participants Experiencing Grade ≥ 3 Treatment-Emergent Adverse Events (TEAEs)	First dose date up to 1.3 years plus 70 days	TEAEs were defined as any AE that began on or after the date of first dose of study treatment up to the date of last dose of study treatment plus 70 days or the day before initiation of new anti-AML therapy including SCT, whichever occurred first. Percentages were rounded-off.
Percentage of Participants Experiencing Grade 3 or 4 Treatment-Emergent Laboratory Abnormalities	First dose date up to 1.3 years plus 70 days	Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study treatment plus 70 days or the day before initiation of any new anti-AML therapy including SCT, whichever occurred first. Percentages were rounded-off.
Serum Concentration of Magrolimab	Predose on Days 1, 4, 8, 11; Days 29 and 57 Predose and 1 hour Postdose; Predose on Days 113, 169, 253, 281 and 337
Percentage of Participants With Anti-Magrolimab Antibodies	Up to 2 years	Percentages were rounded-off.

Trial Locations

Locations (156): Fiona Stanley Hospital
🇦🇺
Murdoch, Western Australia, Australia
Royal Adelaide Hospital
🇦🇺
Adelaide, South Australia, Australia
Massachusetts General Hospital
🇺🇸
Boston, Massachusetts, United States
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
🇺🇸
Duarte, California, United States
USC/ Norris Comprehensive Cancer Center
🇺🇸
Los Angeles, California, United States
Ronald Reagan UCLA Medical Center
🇺🇸
Los Angeles, California, United States
UC Irvine Health
🇺🇸
Orange, California, United States
Mayo Clinic Florida
🇺🇸
Jacksonville, Florida, United States
AdventHealth Orlando
🇺🇸
Orlando, Florida, United States
Memorial Cancer Institute
🇺🇸
Pembroke Pines, Florida, United States
Moffitt Cancer Center
🇺🇸
Tampa, Florida, United States
Winship Cancer Institute
🇺🇸
Atlanta, Georgia, United States
The University of Chicago Medical Centre
🇺🇸
Chicago, Illinois, United States
Northwestern Memorial Hospital/Main Lab
🇺🇸
Chicago, Illinois, United States
Tulane Medical center
🇺🇸
New Orleans, Louisiana, United States
University of Kentucky Medical Center
🇺🇸
Lexington, Kentucky, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
🇺🇸
Baltimore, Maryland, United States
Dana-Farber Cancer Institute
🇺🇸
Boston, Massachusetts, United States
Mayo Clinic Cancer Center Outpatient Pharmacy
🇺🇸
Rochester, Minnesota, United States
MidAmerica Division, Inc., c/o Research Medical Center
🇺🇸
Kansas City, Missouri, United States
SSM Health Saint Louis University Hospital
🇺🇸
Saint Louis, Missouri, United States
Roswell Park Cancer Institute
🇺🇸
Buffalo, New York, United States
Columbia University Medical Center - Herbert Irving Pavilion
🇺🇸
New York, New York, United States
UNC Hospitals, The University of North Carolina at Chapel Hill
🇺🇸
Chapel Hill, North Carolina, United States
The Ohio State University Wexner Medical Center/ James Cancer Hospital
🇺🇸
Columbus, Ohio, United States
Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization
🇺🇸
Philadelphia, Pennsylvania, United States
St. Francis Cancer Center
🇺🇸
Greenville, South Carolina, United States
Baylor College of Medicine Medical Center
🇺🇸
Houston, Texas, United States
Prisma Health Cancer Institute
🇺🇸
Greenville, South Carolina, United States
The University of Texas MD Anderson Cancer Center
🇺🇸
Houston, Texas, United States
Calvary Master Newcastle
🇦🇺
Waratah, New South Wales, Australia
Princess Alexandra Hospital
🇦🇺
Woolloongabba, Queensland, Australia
Froedtert Hospital / Medical College of Wisconsin
🇺🇸
Milwaukee, Wisconsin, United States
Westmead Hospital / Department of Haematology and Bone Marrow Transplantation
🇦🇺
Westmead, New South Wales, Australia
Andrew Love Cancer Centre, University Hospital Geelong
🇦🇺
Geelong, Victoria, Australia
The Alfred
🇦🇺
Melbourne, Victoria, Australia
St Vincents Hospital Melbourne
🇦🇺
Melbourne, Victoria, Australia
AZ Delta vzw
🇧🇪
Roeselare, Belgium
CIUSSS de L'Est-de-L'Ile-de- Montreal - Hopital Maisonneuve-Rosemont
🇨🇦
Montreal, Canada
McGill University Health Centre
🇨🇦
Montreal, Canada
Sunnybrook Research Institute
🇨🇦
Toronto, Canada
Princess Margaret Cancer Centre
🇨🇦
Toronto, Canada
CHU d'Angers
🇫🇷
Angers cedex, France
CHU de Caen
🇫🇷
Caen cedex, France
CHRU Lille - Hospital Claude Huriez
🇫🇷
Lille, France
CHU Limoges
🇫🇷
Limoges, France
Central Hospital Lyon Sud
🇫🇷
Lyon, France
CHU de Nantes, Hotel Dieu
🇫🇷
Nantes, France
Institut Paoli Calmettes
🇫🇷
Marseille, France
CHU Nice - Hopital Archet 1
🇫🇷
Nice, France
Gustave Roussy
🇫🇷
Paris, France
Hopital Haut-Leveque
🇫🇷
Pessac, France
IUCT Oncopole
🇫🇷
Toulouse, France
Department of Hematology and Oncology, Braunschweig Community Hospital
🇩🇪
Braunschweig, Germany
Hopitaux de Brabois
🇫🇷
Vandoeuvre-lès-Nancy, France
Uniklinik RWTH Aachen, Medizinische Klunuk IV - Klinik fur Hamatologie, Onkologie, Hamastaseologie und Srammzelltransplantation
🇩🇪
Aachen, Germany
Dept. of Medicine II, University Hospital Hamburg-Eppendorf
🇩🇪
Hamburg, Germany
Universitätsklinikum Düsseldorf -Klinik für Hämatologie, Onkologie und Klinische Immunologie
🇩🇪
Dusseldorf, Germany
Universitatsklinikum Schleswig-Holstein
🇩🇪
Kiel, Germany
Universitatsklinikum Koln
🇩🇪
Köln, Germany
Klinikum Ludwigshafen Medizinische Klinik A
🇩🇪
Ludwigshafen, Germany
Klinikum rechts der Isar der Technischen Universitat Munchen, Klinik und Poliklinik fur Innere Medizin III
🇩🇪
Muenchen, Germany
LMU - Klinikum der Universitat Munchen, Medizinische Klinik und Poliklinik III, Campus Grosshadern
🇩🇪
München, Germany
Universitatsklinikum Ulm, Zentrum fur Innere Medizin, Innere Medizin III
🇩🇪
Ulm, Germany
Azienda Ospedaliero Universitaria delle Marche
🇮🇹
Ancona, Italy
AOU Consorziale Policlinico Bari
🇮🇹
Bari, Italy
Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola-Malphigi U.O Ematologia
🇮🇹
Bologna, Italy
SC Ematologia, Azienda Ospedaliera di Perugia - Santa Maria della Misericordia
🇮🇹
Perugia, Italy
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRS - Oncologia Medica
🇮🇹
Meldola, Italy
Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli U.O.S.C. di Ematologia con Trapianto di Midollo Osseo
🇮🇹
Napoli, Italy
AORM - AO Riuniti Marche Norde - Pesaro Presidio "San Salvatore" - Muraglia
🇮🇹
Pesaro, Italy
Fondazione PTV Policinico Tor Vergata
🇮🇹
Roma, Italy
SCDU Ematologia e Terrapie cellulari AO O Ordine Mauriziano Torino
🇮🇹
Torino, Italy
ASST Sette Laghi - Ospedale di Circolo e Fondazione Macchi
🇮🇹
Varese, Italy
Kobe City Medical Center General Hospital
🇯🇵
Kobe-city, Japan
Ehime Prefectural Center Hospital
🇯🇵
Matsuyama, Japan
Nagasaki University Hospital
🇯🇵
Nagasaki, Japan
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital
🇯🇵
Nagoya-Shi, Japan
Okayama University Hospital
🇯🇵
Okayama-Shi, Japan
Kindai University Hospital
🇯🇵
Osakasayama, Japan
National University Corporation Tohoku University Tohoku University Hospital
🇯🇵
Sendai, Japan
NTT Medical Center Tokyo
🇯🇵
Shinagawa-Ku, Japan
Yamagata University Hospital
🇯🇵
Yamagata, Japan
Hospital General Universitario de Alicante
🇪🇸
Alicante, Spain
Hospital del la Santa Creu i Sant Pau
🇪🇸
Barcelona, Spain
Hospital Universitari Vall d'Hebron
🇪🇸
Barcelona, Spain
Hospital Clinic de Barcelona
🇪🇸
Barcelona, Spain
Complejo Asistencial Universitario de Burgos/H.U. de Burgos
🇪🇸
Burgos, Spain
Institut Catala d'Oncologia
🇪🇸
Barcelona, Spain
Hospital Universitario Reina Sofia
🇪🇸
Cordoba, Spain
Complejo Hospitalario San Pedro de Alcantara
🇪🇸
Cáceres, Spain
Hospital Universitario de Gran Canaria Doctor Negrin
🇪🇸
Las Palmas de Gran Canaria, Spain
Hospital General Universitario Gregorio Maranon
🇪🇸
Madrid, Spain
Hospital Universitario de La Princesa
🇪🇸
Madrid, Spain
MD Anderson Cancer Center Madrid
🇪🇸
Madrid, Spain
Hospital Regional Universitario de Malaga
🇪🇸
Malaga, Spain
Hospital Universitario Central de Asturias
🇪🇸
Oviedo, Spain
Clinica Universidad de Navarra - Pamplona (Main Site)
🇪🇸
Pamplona, Spain
Complejo Asistencial Universitario de Salamanca - Hsopital Clinico
🇪🇸
Salamanca, Spain
Hospital U. Marques de Valdecilla
🇪🇸
Santander, Spain
Hospital Universitari I Politècnic La Fe
🇪🇸
Valencia, Spain
Hospital Clinico Universitario de Valencia
🇪🇸
Valencia, Spain
Universitetssjukhus, Hematologimottagnungen
🇸🇪
Lund, Sweden
United Lincolnshire Hospitals NHS Trust, Pilgrim Hospital, Sibsey Road
🇬🇧
Boston, United Kingdom
University of Kansas Hospital
🇺🇸
Fairway, Kansas, United States
Royal Perth Hospital
🇦🇺
Perth, Western Australia, Australia
Queen Mary Hospital
🇭🇰
Hong Kong, Hong Kong
Hyogo Prefectural Amagasaki General Medical Center
🇯🇵
Amagasaki, Japan
Fukushima Medical University Hospital
🇯🇵
Fukushima-Shi, Japan
Tokai University School of Medicine
🇯🇵
Isehara, Japan
Kanazawa University Hospital
🇯🇵
Kanazawa, Japan
Inselspital, Universitatsspital Bern - Universitatsklinik fur Medizinisch Onkologie
🇨🇭
Berne, Switzerland
University Hospitals Birmingham NHS Foundation Trust
🇬🇧
Birmingham, United Kingdom
Canberra Hospital
🇦🇺
Garran, Australian Capital Territory, Australia
Algemeen Ziekenhuis Sint-Jan Brugge-Oostende AV
🇧🇪
Brugge, Belgium
Aiiku Hospital
🇯🇵
Hokkaido, Japan
Hospital of the University of Occupational and Environmental Health, Japan
🇯🇵
Kitakyushu-shi, Japan
Uniklinikum Salzburg, Universitatsklinik f. Innere Medizin III der PMU
🇦🇹
Salzburg, Austria
Univ. -Klinik für Hämatologie und Internistische Onkologie, Kepler Universitätskilkun GmbHMed
🇦🇹
Linz, Austria
Grand Hôpital De Charleroi - Notre Dame
🇧🇪
Charleroi, Belgium
Universitair Ziekenhuis Gent
🇧🇪
Gent, Belgium
Kyushu University Hospital
🇯🇵
Fukuoka, Japan
Universitair Ziekenhuis Brussel
🇧🇪
Brussels, Belgium
Universitaire Ziekenhuis Antwerpen
🇧🇪
Edegem, Belgium
University of Yamanashi Hospital
🇯🇵
Chuo-City, Japan
Chiba Aoba Municipal Hospital
🇯🇵
Chiba, Japan
Gunmaken Saiseikai Maebashi Hospital
🇯🇵
Maebashi, Japan
Osaka Metropolitan University Hospital
🇯🇵
Osaka-Shi, Japan
National Cancer Center Hospital East
🇯🇵
Kashiwa, Japan
Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital
🇯🇵
Nagoya, Japan
University of Fukui Hospital
🇯🇵
Yoshida-gun, Japan
Universitatsspital Basel - Klinik fur Hamatrologie, Bereich Innere Medizin
🇨🇭
Basel, Switzerland
University College London Hospitals NHS Foundation Trust
🇬🇧
London, United Kingdom
Aalborg University Hospital
🇩🇰
Aalborg, Denmark
Odense University Hospital
🇩🇰
Odense C, Denmark
University of Alabama at Birmingham
🇺🇸
Birmingham, Alabama, United States
Colorado Blood Cancer Institute
🇺🇸
Denver, Colorado, United States
Miami Cancer Institute
🇺🇸
Miami, Florida, United States
Duke Blood Cancer Center
🇺🇸
Durham, North Carolina, United States
University of Oklahoma Health Sciences Center - OU Health Stephenson Cancer Center
🇺🇸
Oklahoma City, Oklahoma, United States
Huntsman Cancer Institute ,The University of Utah
🇺🇸
Salt Lake City, Utah, United States
Tom Baker Cancer Center
🇨🇦
Calgary, Canada
Dept. of Hematology, Oncology and Tumor Immunology, Charite- University Medicine Berlin, Campus Virchow Klinikum
🇩🇪
Berlin, Germany
Universitatsklinikum Carl Gustav Carus Dresden an der Technische Universitat Dresden, Medizinische Klinik und Poliklinik 1, Bereich Hamatologie
🇩🇪
Dresden, Germany
Universitatsklinikum Heidelberg, Innere Medizin V, Hamatologie, Onkologie und Rheumatologie
🇩🇪
Heidelberg, Germany
Cambridge University Hospital NHS Foundation Trust
🇬🇧
Cambridge, United Kingdom
Cardiff and Vale University Health Board
🇬🇧
Cardiff Wales, United Kingdom
Barts Health NHS Trust
🇬🇧
City of London, United Kingdom
NHS Tayside
🇬🇧
Dundee, United Kingdom
Beatson West of Scotland Cancer Centre
🇬🇧
Glasgow, United Kingdom
King's College NHS Foundation Trust
🇬🇧
London, United Kingdom
Oxford University Hospital NHS Foundation Trust
🇬🇧
Oxford, United Kingdom
The Royal Marsden NHS Foundation Trust
🇬🇧
Sutton, United Kingdom
The Christie NHS Foundation Trust
🇬🇧
Withington, United Kingdom
Queen Elizabeth II Health Sciences Centre
🇨🇦
Halifax, Canada
Prince of Wales Hospital, The Chinese University of Hong Kong
🇭🇰
Hong Kong, Hong Kong